Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Ceftolozane/tazobactam for treatment of severe ESBL-producing enterobacterales infections: A multicenter nationwide clinical experience (CEFTABUSE II Study)
Open Forum Infectious Diseases, Volume 7, No. 5, Year 2020
Notification
URL copied to clipboard!
Description
Background: Few data are reported in the literature about the outcome of patients with severe extended-spectrum ß-lactamase-producing Enterobacterales (ESBL-E) infections treated with cefolozane/tazobactam (C/T), in empiric or defnitive therapy. Methods: A multicenter retrospective study was performed in Italy (June 2016-June 2019). Successful clinical outcome was defined as complete resolution of clinical signs/symptoms related to ESBL-E infection and lack of microbiological evidence of infection. The primary end point was to identify predictors of clinical failure of C/T therapy. Results: C/T treatment was documented in 153 patients: pneumonia was the most common diagnosis (n = 46, 30%), followed by 34 cases of complicated urinary tract infections (22.2%). Septic shock was observed in 42 (27.5%) patients. C/T was used as empiric therapy in 46 (30%) patients and as monotherapy in 127 (83%) patients. Favorable clinical outcome was observed in 128 (83.7%) patients; 25 patients were considered to have failed C/T therapy. Overall, 30-day mortality was reported for 15 (9.8%) patients. At multivariate analysis, Charlson comorbidity index >4 (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.9-3.5; P =.02), septic shock (OR, 6.2; 95% CI, 3.8-7.9; P <.001), and continuous renal replacement therapy (OR, 3.1; 95% CI, 1.9-5.3; P =.001) were independently associated with clinical failure, whereas empiric therapy displaying in vitro activity (OR, 0.12; 95% CI, 0.01-0.34; P <.001) and adequate source control of infection (OR, 0.42; 95% CI, 0.14-0.55; P <.001) were associated with clinical success. Conclusions: Data show that C/T could be a valid option in empiric and/or targeted therapy in patients with severe infections caused by ESBL-producing Enterobacterales. Clinicians should be aware of the risk of clinical failure with standard-dose C/T therapy in septic patients receiving CRRT. © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Authors & Co-Authors
Bassetti, Matteo
Italy, Genoa
Università Degli Studi Di Genova
Vena, Antonio
Italy, Genoa
Università Degli Studi Di Genova
Giacobbe, Daniele Roberto
Italy, Genoa
Università Degli Studi Di Genova
Falcone, Marco
Italy, Pisa
Università Di Pisa
Tiseo, Giusy
Italy, Pisa
Università Di Pisa
Giannella, Maddalena
Italy, Bologna
Alma Mater Studiorum Università Di Bologna
Meschiari, Marianna
Italy, Modena
Università Degli Studi Di Modena e Reggio Emilia
Rovelli, Cristina
Italy, Varese
Azienda Ospedaliera Ospedale Di Circolo e Fondazione Macchi Di Varese
Losito, Angela Raffaella
Italy, Rome
Fondazione Policlinico Universitario Agostino Gemelli Irccs
Italy, Rome
Università Cattolica Del Sacro Cuore, Campus Di Roma
Tumbarello, Mario
Italy, Rome
Università Cattolica Del Sacro Cuore, Campus Di Roma
Tascini, Carlo
Italy, Naples
Azienda Ospedaliera D. Cotugno
Grossi, Paolo Antonio
Italy, Varese
Azienda Ospedaliera Ospedale Di Circolo e Fondazione Macchi Di Varese
Mastroianni, Claudio Maria
Italy, Rome
Sapienza Università Di Roma
Italy, Rome
Azienda Ospedaliera Universitaria Policlinico Umberto I
Mussini, Cristina
Italy, Modena
Università Degli Studi Di Modena e Reggio Emilia
Viale, Pierluigi
Italy, Bologna
Alma Mater Studiorum Università Di Bologna
Menichetti, Francesco
Italy, Pisa
Università Di Pisa
Italy, Pisa
Azienda Ospedaliero Universitaria Pisana
Viscoli, Claudio
Italy, Genoa
Università Degli Studi Di Genova
Italy, Pisa
Azienda Ospedaliero Universitaria Pisana
Russo, Alessandro
Italy, Pisa
Università Di Pisa
Italy, Pisa
Azienda Ospedaliero Universitaria Pisana
Castaldo, Nadia
Italy, Udine
Presidio Ospedaliero Universitario Santa Maria Della Misericordia , Udine
Pecori, Davide
Italy, Udine
Presidio Ospedaliero Universitario Santa Maria Della Misericordia , Udine
Merelli, M.
Italy, Udine
Presidio Ospedaliero Universitario Santa Maria Della Misericordia , Udine
Peghin, Maddalena
Italy, Udine
Presidio Ospedaliero Universitario Santa Maria Della Misericordia , Udine
Viale, Pierluigi
Italy, Bologna
Alma Mater Studiorum Università Di Bologna
Cattelan, Anna María
Italy, Padua
Azienda Ospedale Università Padova
Raffaelli, F.
Italy, Rome
Università Cattolica Del Sacro Cuore, Campus Di Roma
Petrosillo, Nicola
Italy, Rome
Irccs Istituto Nazionale Malattie Infettive Lazzaro Spallanzani
Rizzardini, Giuliano
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Coen, Massimo
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Passerini, Matteo
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Maraolo, Alberto Enrico
Italy, Naples
Università Degli Studi Di Napoli Federico Ii
Parruti, Giustino
Italy, Pescara
Pescara General Hospital
Girardis, Massimo
Italy, Modena
Azienda Ospedaliero - Universitaria Di Modena
Cascio, Antonio
Italy, Palermo
Università Degli Studi Di Palermo
Malfatto, Emanuele Nadir
Italy, Milan
Ospedale San Paolo
Statistics
Citations: 47
Authors: 34
Affiliations: 25
Identifiers
Doi:
10.1093/ofid/ofaa139
ISSN:
23288957
Study Design
Cohort Study
Case-Control Study